iRadimed is a high-quality small-cap franchise with a wide economic moat, best-in-class margins, and a near-perfect financial health score, but the shares trade at a forward earnings multiple of 38.6x — a valuation that leaves little margin of safety — and an elevated options skew signals meaningful near-term uncertainty.
Thesis pillars
- Wide Moat Best In Class Quality→Stable
- Elevated Options Skew Uncertainty↓Deteriorating
- Consistent Earnings Outperformance↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 6, 2026
iRadimed Corporation (IRMD) Stock Analysis
Temporary headwind edge
Healthcare · Medical Devices
Wait for pullback to $81.90. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $83.93. Engine's entry $81.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI... Read more
Wait for pullback to $81.90. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $83.93. Engine's entry $81.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers. Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Score 5.5/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — iRadimed Corporation
Latest news
- NEWS IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
- NEWS At US$83.95, Is IRADIMED CORPORATION (NASDAQ:IRMD) Worth Looking At Closely? - Simply Wall St — Simply Wall St neutral
- NEWS At US$83.95, Is IRADIMED CORPORATION (NASDAQ:IRMD) Worth Looking At Closely? - Simply Wall Street — Simply Wall Street neutral
- NEWS Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report - Yahoo Finance — Yahoo Finance positive
- NEWS Iradimed CEO Roger Susi sells $694k in common stock By Investing.com - Investing.com Australia — Investing.com Australia negative
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMRidium infusion pumps and 3880 monitoring system10-K Item 1A: 'Our current revenue and profitability are significantly dependent on the sale of the MRidium MRI compatible IV infusion pump systems, the 3880 MRI compatible patient vital signs monitoring system'
- HIGHSuppliersingle-source suppliers10-K Item 1A: 'Considering our dependence on third-party suppliers, several of which are single-source suppliers, we are subject to inherent uncertainties and risks'
- LOWGeographicoutside the U.S.16%10-K Item 1A: 'Our revenues outside the U.S. in fiscal year 2025 represented approximately 16 percent of our net revenues.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $81.90. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $83.93. Engine's entry $81.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers. Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Target $100.30 (+19.5%), stop $78.06 (−7.5%), A.R:R 3.9:1. Score 5.5/10, moderate confidence.
Take-profit target: $100.30 (+19.5% upside). Target $100.30 (+19.5%), stop $78.06 (−7.5%), A.R:R 3.9:1. Stop-loss: $78.06.
Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system; Concentration risk — Supplier: single-source suppliers; Expensive valuation.
iRadimed Corporation trades at a P/E of 46.9 (forward 34.2). TrendMatrix value score: 3.8/10. Verdict: Buy (Wait for Entry).
9 analysts cover IRMD with a consensus score of 4.0/5. Average price target: $118.
What does iRadimed Corporation do?IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible...
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.